A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma

Pre-clinical data demonstrate a pivotal role for interleukin (IL)-13 in the development and maintenance of asthma. This study assessed the effects of tralokinumab, an investigational human IL-13-neutralising immunoglobulin G4 monoclonal antibody, in adults with moderate-to-severe uncontrolled asthma...

Descripción completa

Detalles Bibliográficos
Autores principales: Piper, Edward, Brightling, Christopher, Niven, Robert, Oh, Chad, Faggioni, Raffaella, Poon, Kwai, She, Dewei, Kell, Chris, May, Richard D., Geba, Gregory P., Molfino, Nestor A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3561510/
https://www.ncbi.nlm.nih.gov/pubmed/22743678
http://dx.doi.org/10.1183/09031936.00223411

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3561510/
https://www.ncbi.nlm.nih.gov/pubmed/22743678
http://dx.doi.org/10.1183/09031936.00223411

Ejemplares similares